amiodarone vs sofosbuvir/velpatasvir
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of amiodarone and sofosbuvir/velpatasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Antiarrhythmics: amiodarone Effect on amiodarone, sofosbuvir, velpatasvir, and voxilaprevir concentrations unknown Coadministration of amiodarone with VOSEVI may result in serious symptomatic bradycardia. Coadministration of amiodarone with VOSEVI is not recommended; if coadministration is required, cardiac monitoring is recommended [see Warnings and Precautions (5.3) ].
Cordarone, Pacerone
Epclusa
Amiodarone (Pacerone) is a medicine used to treat life-threatening, irregular heartbeats. It helps to restore a normal heart rhythm when other medicines don't work or can't be used.
Vosevi is a drug that combines three medicines into one tablet. It is used to treat hepatitis C in adults who have already tried other treatments.
This medicine treats very fast, irregular heartbeats in the ventricles (lower chambers of the heart). It is used when these irregular heartbeats are life-threatening. It is also used when other medicines don't work well enough or cause too many side effects. This medicine is for adults.
Vosevi treats chronic hepatitis C (HCV) infection in adults. It is for those without cirrhosis or with compensated cirrhosis (Child-Pugh A). You can use it if you have genotype 1, 2, 3, 4, 5, or 6 HCV. You must have already been treated with a hepatitis C medicine containing an NS5A inhibitor, or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).
Amiodarone affects the electrical signals in your heart. It slows down these signals, which helps your heart beat normally. This medicine can help prevent dangerous, fast heart rhythms.
Vosevi contains sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir blocks a protein called NS5B polymerase that the hepatitis C virus needs to multiply. Velpatasvir blocks the NS5A protein, and voxilaprevir blocks the NS3/4A protease protein, both of which the virus also needs.
- • Low thyroid levels (hypothyroidism)
- • High thyroid levels (hyperthyroidism)
- • Heart failure
- • Irregular heartbeats
- • Problems with the heart's natural pacemaker (SA node dysfunction)
- • Headache
- • Fatigue (feeling tired)
- • Diarrhea
- • Nausea (feeling sick to your stomach)
- Dyspnoea 1,158
- Asthenia 975
- Fatigue 895
- Nausea 606
- Cough 597
- Feeling tired 2,307
- Hepatitis C infection 1,734
- Headache 1,639
- Feeling sick to your stomach 1,386
- Low red blood cell count 1,185
This medicine can cause serious problems with your lungs, liver, and heart. Lung problems can be fatal. Your doctor will check your lungs with X-rays and breathing tests. Liver problems can also be fatal. Your doctor will check your liver with blood tests. This medicine can also make irregular heartbeats worse. You will likely start this medicine in the hospital where your heart can be monitored.
Vosevi can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Before starting Vosevi, your doctor will test you for Hepatitis B. They will also monitor you during and after treatment.
This medicine can harm your unborn baby. It can cause thyroid problems, slow heart rate, and brain development issues. Do not breastfeed while taking this medicine.
It is not known if Vosevi can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Vosevi passes into breast milk, so discuss this with your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare amiodarone with
How to Read This amiodarone vs sofosbuvir/velpatasvir Comparison
amiodarone is classified in the Class III Antiarrhythmic drug class, while sofosbuvir/velpatasvir sits within the NS5B/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, amiodarone has 4,231 submissions while sofosbuvir/velpatasvir has 8,251. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to using these drugs at the same time can cause your heart rate to slow down to a level that may be dangerous.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for amiodarone or sofosbuvir/velpatasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.